Depression and disease-modifying agents in multiple sclerosis: a propensity matched comparison

被引：0
|
作者：
Ontaneda, D. [1 ]
Cohen, J. A. [1 ]
机构：
[1] Cleveland Clin, Mellen Ctr, Cleveland, OH 44106 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2011年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P709
引用
收藏
页码：S314 / S314
页数：1
相关论文
共 50 条
  • [1] Disease-modifying agents in multiple sclerosis
    Coyle, P. K.
    [J]. ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2009, 12 (04) : 273 - 282
  • [2] Multiple Sclerosis: Overview of Disease-Modifying Agents
    Finkelsztejn, Alessandro
    [J]. PERSPECTIVES IN MEDICINAL CHEMISTRY, 2014, 6 : 65 - 72
  • [3] Factors influencing interruption of disease-modifying agents in multiple sclerosis
    Nociti, V.
    Padua, L.
    Mirabella, M.
    Patanella, A. K.
    Sancricca, C.
    Caggiula, M.
    Frisullo, G.
    Angelucci, E.
    Tonali, P. A.
    Batocchi, A. P.
    [J]. JOURNAL OF NEUROLOGY, 2006, 253 : 143 - 143
  • [4] Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis
    Vartanian, TK
    Zamvil, SS
    Fox, E
    Sorensen, PS
    [J]. NEUROLOGY, 2004, 63 (11) : S42 - S49
  • [5] Risk of depression in multiple sclerosis across disease-modifying therapies
    Longinetti, Elisa
    Frisell, Thomas
    Englund, Simon
    Reutfors, Johan
    Fang, Fang
    Piehl, Fredrik
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (04) : 632 - 641
  • [6] Effectiveness of disease-modifying agents in multiple sclerosis: a longitudinal population-based comparison
    Veugelers, P
    Bhan, V
    Fisk, JD
    Brown, MG
    Murray, TJ
    Stadnyk, K
    Sketris, IS
    MacKinnon-Cameron, D
    [J]. MULTIPLE SCLEROSIS, 2005, 11 : S7 - S8
  • [7] Disease-modifying therapies for multiple sclerosis
    De Angelis, Floriana
    John, Nevin A.
    Brownlee, Wallace J.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [8] Multiple sclerosis and disease-modifying therapies
    Minen, Mia T.
    Karceski, Steven
    [J]. NEUROLOGY, 2011, 77 (04) : E26 - E26
  • [9] Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis
    Earla, Jagadeswara Rao
    Li, Jieni
    Hutton, George J.
    Johnson, Michael L.
    Aparasu, Rajender R.
    [J]. PHARMACOTHERAPY, 2023, 43 (06): : 473 - 484
  • [10] Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents
    Amato, MP
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (10) : 2115 - 2126
12345